Sekar Kathiresan - Mar 18, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Mar 18, 2022
Transactions value $
$199,964
Form type
4
Date filed
3/22/2022, 07:41 AM
Previous filing
Feb 15, 2022
Next filing
Jul 15, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $200K +69.7K +17.08% $2.87* 478K Mar 18, 2022 Direct F1
holding VERV Common Stock 81K Mar 18, 2022 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 81K Mar 18, 2022 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -69.7K -10.32% $0.00 605K Mar 18, 2022 Common Stock 69.7K $2.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,315 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
F2 The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.